<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536718</url>
  </required_header>
  <id_info>
    <org_study_id>NCRN-CRUK-GLACIER</org_study_id>
    <secondary_id>CDR0000566209</secondary_id>
    <secondary_id>EU-20760</secondary_id>
    <secondary_id>MREC 06/Q1702/64</secondary_id>
    <secondary_id>CRUK-GLACIER</secondary_id>
    <nct_id>NCT00536718</nct_id>
  </id_info>
  <brief_title>Genetics of Women With Lobular Carcinoma in Situ of the Breast</brief_title>
  <official_title>GLACIER: A Study to Investigate the Genetics of LobulAr Carcinoma In Situ in EuRope</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Gathering information about genetic changes in patients with lobular carcinoma in&#xD;
      situ of the breast may help doctors learn more about the disease and find better methods of&#xD;
      treatment.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the genetics of women with lobular carcinoma in situ&#xD;
      of the breast.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Identify inherited variation that predisposes women to develop lobular carcinoma in situ&#xD;
           (LCIS) of the breast.&#xD;
&#xD;
        -  Identify the frequency of these variants and determine the effect they have on tumor&#xD;
           risk.&#xD;
&#xD;
        -  Determine how worthwhile it would be to test for these variants in the clinical setting&#xD;
           so that those at higher risk could be identified, counseled, and screened.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Analysis of genetic changes within LCIS with the aim of identifying cases of LCIS which&#xD;
           may progress to invasive cancer.&#xD;
&#xD;
      OUTLINE: Patients and control participants undergo blood collection. DNA is extracted from&#xD;
      blood samples and used to genotype at selected polymorphisms, compare allele frequencies&#xD;
      (used to associate alleles with disease) using a genome-wide single nucleotide polymorphism&#xD;
      (SNP) screen. Archival tumor samples (if available) from patients are used for DNA-, RNA-, or&#xD;
      protein-based analyses.&#xD;
&#xD;
      All participants complete a questionnaire about family history, a brief medical history, and&#xD;
      provide epidemiological data to a genetic counselor. Participants identified to be at risk&#xD;
      for known hereditary predisposition to cancer will be referred to a clinical genetics&#xD;
      service. Individual results of this study are not disclosed to participants.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 2,000 participants (1,000 patients and 1,000 matched controls)&#xD;
      will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Inherited variation predisposing development of lobular carcinoma in situ (LCIS) of the breast in women</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and effect of variants on tumor risk</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical setting variant test value in identifying, counseling and screening those women at higher risk</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>LCIS genetic changes which may progress to invasive cancer</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>molecular diagnostic method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical chart review</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Current or prior diagnosis of lobular carcinoma in situ (LCIS) of the breast,&#xD;
                  including any of the following cases:&#xD;
&#xD;
                    -  Pure LCIS&#xD;
&#xD;
                    -  LCIS with subsequent development of invasive breast cancer of any&#xD;
                       morphological subtype&#xD;
&#xD;
                    -  LCIS presenting as an incidental finding together with invasive breast&#xD;
                       cancer of any morphological subtype&#xD;
&#xD;
               -  Control participant matched for age and ethnicity to each LCIS patient&#xD;
&#xD;
                    -  Not affected by LCIS&#xD;
&#xD;
                    -  No history of ductal carcinoma in situ of the breast&#xD;
&#xD;
                    -  No breast cancer&#xD;
&#xD;
                    -  No relative (up to 2nd degree) who has been affected by breast cancer&#xD;
&#xD;
                    -  Male or female&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elinor Sawyer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>London Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rebecca Roylance, MD</last_name>
    <affiliation>Barts and the London School of Medicine and Dentistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Basildon University Hospital</name>
      <address>
        <city>Basildon</city>
        <state>England</state>
        <zip>SS16 5NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1268-533-911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derbyshire Royal Infirmary</name>
      <address>
        <city>Derby</city>
        <state>England</state>
        <zip>DE1 2QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1332-347-141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-113-243-2799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-7188-7188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-3299-9000</phone>
      <email>info@kingsch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Research Institute</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC2A 3PX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elinor Sawyer, MD</last_name>
      <phone>44-20-7269-2884</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southend University Hospital NHS Foundation Trust</name>
      <address>
        <city>Westcliff-On-Sea</city>
        <state>England</state>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1702-435-555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bronglais District General Hospital</name>
      <address>
        <city>Aberystwyth</city>
        <state>Wales</state>
        <zip>SY23 1ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1970-623-131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-7377-7000</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <study_first_submitted>September 27, 2007</study_first_submitted>
  <study_first_submitted_qc>September 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2007</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>invasive lobular breast carcinoma with predominant in situ component</keyword>
  <keyword>invasive lobular breast carcinoma</keyword>
  <keyword>lobular breast carcinoma in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Lobular</mesh_term>
    <mesh_term>Breast Carcinoma In Situ</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

